About GB Sciences (OTCMKTS:GBLX)
GB Sciences, Inc., formerly Growblox Sciences, Inc., is engaged in developing and utilizing technologies in plant biology, cultivation and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates and cannabinoid therapies. It seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies and treatments for a range of ailments. It intends to conduct its business operations, through its subsidiaries in approximately three operating units, which include Solutions, Sciences and Product divisions. The Solutions division involves the development and use of its suite of controlled-climate indoor agricultural technology growing and cultivation Suites, including TissueBLOX, GrowBLOX, CureBLOX and ExtractionLAB. The Science division is engaged in preclinical testing of its biopharmaceutical cannabinoid product prototypes to begin future human clinical trials.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-158.06%
Return on Assets-100.57%
Frequently Asked Questions for GB Sciences (OTCMKTS:GBLX)
What is GB Sciences' stock symbol?
GB Sciences trades on the OTCMKTS under the ticker symbol "GBLX."
How were GB Sciences' earnings last quarter?
GB Sciences, Inc. (OTCMKTS:GBLX) announced its quarterly earnings results on Monday, November, 14th. The company reported ($0.04) EPS for the quarter. GB Sciences had a negative net margin of 5,761.07% and a negative return on equity of 158.06%. View GB Sciences' Earnings History.
Who are some of GB Sciences' key competitors?
Some companies that are related to GB Sciences include Peninsula Energ (PENMF), Emergent Capital (EMGC), NetDimensions (Holdings) (NETDY), POET Technologies (POETF), Perpetual Energy (PMGYF), MobileSmith (MOST), IntelGenx Technologies Corp. (IGXT), Jds Uniphase Canada (JDUCF), OptimizeRx Corp. (OPRX), United Cannabis Corp (CNAB), OmniComm Systems (OMCM), Pioneer Power Solutions (PPSI), Singlepoint (SING), Biosig Technologies (BSGM), H2O Innovation (HEOFF), Generation Next Franchise Brands (VEND), Genco Shipping & Trading Limited (GNKOQ) and Zenyatta Ventures Ltd (ZENYF).
Who are GB Sciences' key executives?
GB Sciences' management team includes the folowing people:
- John Poss, Chairman of the Board, President, Chief Executive Officer (Age 69)
- Leslie Bocskor, Independent Vice Chairman of the Board (Age 52)
- Ksenia Griswold, Chief Financial Officer, Vice President (Age 34)
- Krin Ellery Kuethe, Chief Operating Officer (Age 32)
- Andrea Small-Howard Ph.D., Chief Science Officer, Director (Age 48)
- Shane Terry, Independent Director (Age 38)
How do I buy GB Sciences stock?
Shares of GB Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GB Sciences' stock price today?
One share of GB Sciences stock can currently be purchased for approximately $0.24.
How big of a company is GB Sciences?
GB Sciences has a market capitalization of $30.79 million.
How can I contact GB Sciences?
GB Sciences' mailing address is 6450 Cameron St Ste 110A, LAS VEGAS, NV 89118-4337, United States. The company can be reached via phone at +1-888-8953594.
MarketBeat Community Rating for GB Sciences (GBLX)MarketBeat's community ratings are surveys of what our community members think about GB Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for GB Sciences (OTCMKTS:GBLX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for GB Sciences (OTCMKTS:GBLX)
Analysts' Ratings History for GB Sciences (OTCMKTS:GBLX)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History and Estimates Chart for GB Sciences (OTCMKTS:GBLX)
Earnings History by Quarter for GB Sciences (OTCMKTS GBLX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for GB Sciences (OTCMKTS:GBLX)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for GB Sciences (OTCMKTS:GBLX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for GB Sciences (OTCMKTS GBLX)
Insider Trades by Quarter for GB Sciences (OTCMKTS GBLX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/4/2017||Craig Ellins||Insider||Sell||100,000||$0.26||$26,000.00|| |
|10/6/2016||Lazarus Management Co Llc||Major Shareholder||Sell||785,000||$0.31||$243,350.00|| |
|10/8/2014||Lazarus Management Co Llc||Major Shareholder||Buy||77,700||$0.69||$53,613.00|| |
|10/2/2014||Lazarus Management Co Llc||Major Shareholder||Buy||39,605||$0.85||$33,664.25|| |
|9/29/2014||Lazarus Management Co Llc||Major Shareholder||Buy||64,000||$0.90||$57,600.00|| |
|9/17/2014||Lazarus Management Co Llc||Major Shareholder||Buy||47,640||$0.76||$36,206.40|| |
|8/27/2014||Israel Opportunities F Lazarus||Major Shareholder||Buy||46,625||$1.05||$48,956.25|| |
|8/1/2014||Israel Opportunities F Lazarus||Major Shareholder||Buy||39,800||$1.24||$49,352.00|| |
|7/30/2014||Israel Opportunities F Lazarus||Major Shareholder||Buy||87,077||$1.24||$107,975.48|| |
|7/2/2014||Lazarus Investment Partners Ll||Major Shareholder||Buy||269,632||$1.19||$320,862.08|| |
|6/2/2014||Lazarus Management Co Llc||Major Shareholder||Buy||1,000,000||$0.50||$500,000.00|| |
Latest Headlines for GB Sciences (OTCMKTS GBLX)
|GB Sciences Exceeds Its Gross Revenue Projections for October, Doubles the Industry Average Yield Per Active Flower Light|
finance.yahoo.com - November 15 at 5:36 AM
|GB Sciences is Happy|
finance.yahoo.com - November 13 at 9:50 AM
|The Scientific Advisory Board will oversee the development of GB Sciences’ Cannabis-Based Therapies and Clinical Trials|
globenewswire.com - November 1 at 8:09 PM
|GB Sciences, Inc. Partners With Cura Cannabis Solutions And Enters The Lucrative Cannabis Oil Market In Nevada|
finance.yahoo.com - October 30 at 7:47 PM
|GB Sciences Receives The Prestigious 'Spirit Of The Law' Award|
finance.yahoo.com - October 26 at 7:31 AM
|GB Sciences Increased Sales 400% Since First Harvest|
finance.yahoo.com - October 23 at 6:41 PM
|GB Sciences Obtains Exclusive Worldwide License on a Time-Released Cannabinoid Formulation for Neuropathic Pain|
finance.yahoo.com - October 17 at 7:37 PM
|Marijuana and Cannabis Business Becoming One of the Market's Fastest Grow Industries|
www.nasdaq.com - October 10 at 4:39 PM
|Nanotechnology Research Collaboration with Universidad de Sevilla to Create Time-Released Formulation for GB Sciences' THC-Free Chronic Pain Therapy|
finance.yahoo.com - October 10 at 4:39 PM
|Innovative Partnership Forged Between LSU AgCenter And GB Sciences To Advance The Understanding Of The Cannabis Plant|
finance.yahoo.com - September 18 at 6:30 PM
|Groundbreaking Collaboration Between A Major University And A Medical Cannabis Company|
finance.yahoo.com - September 18 at 6:30 PM
|GB Sciences Inc (GBLX) Insider Sells $26,000.00 in Stock|
www.americanbankingnews.com - August 7 at 8:02 PM
|GB Sciences Joins With Los Coyotes Band Of Cahuilla And Cupeno Indians As It Enters The Gigantic California Cannabis Market|
finance.yahoo.com - August 2 at 7:49 PM
|GB Sciences initiates cannabis-based therapy clinical trials consulting services agreement with Worldwide Clinical Trials|
seekingalpha.com - July 17 at 9:30 AM
|GB Sciences Initiates Cannabis-based Therapy Clinical Trials Consulting Services Agreement with Worldwide Clinical Trials, Inc.|
finance.yahoo.com - July 17 at 9:30 AM
|GB Sciences Inc. Adds Provisional Nevada Recreational Cannabis License for Branded Recreational Products|
finance.yahoo.com - July 10 at 6:53 AM
|Cannabis Industry Weekly Recap 7/7/2017|
finance.yahoo.com - July 8 at 10:59 AM
|GB Sciences Sells First Cannabis Harvest and Officially Enters Revenue Mode|
finance.yahoo.com - July 5 at 7:32 AM
|Cannabis, CBD, Vape Products See Uptick in Sales in Thriving Legal Marijuana Markets|
www.prnewswire.com - May 4 at 12:14 PM
|Marijuana Stocks: How CEOs Can Navigate Market Volatility (And Survive Spicer And Sessions)|
www.benzinga.com - March 10 at 11:30 PM
|GROWBLOX SCIENCES, INC. Files SEC form 8-K/A, Entry into a Material Definitive Agreement|
biz.yahoo.com - February 16 at 5:19 PM
|GROWBLOX SCIENCES, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year|
biz.yahoo.com - December 20 at 9:47 PM
|Cannabis Stocks Stay Ahead In Exploding Legal Marijuana Market|
www.prnewswire.com - November 29 at 5:07 PM
|Cannabis Legalization at the Forefront this Week|
www.bizjournals.com - November 9 at 11:07 AM
|Pot is on the Ballot in Election 2016, but Investors Should Proceed with Caution|
www.thestreet.com - October 27 at 9:50 AM
|GROWBLOX SCIENCES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders|
biz.yahoo.com - October 15 at 9:58 AM
|Awareness Continues to Grow for Medical Uses of Cannabis|
www.prnewswire.com - September 29 at 10:10 AM
|GROWBLOX SCIENCES, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities|
biz.yahoo.com - September 9 at 4:59 PM
|GROWBLOX SCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Princi|
biz.yahoo.com - August 11 at 5:24 PM
|GROWBLOX SCIENCES, INC. Files SEC form 10-K, Annual Report|
biz.yahoo.com - July 14 at 5:31 PM
|GROWBLOX SCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement|
biz.yahoo.com - June 7 at 5:17 PM
GB Sciences (OTCMKTS GBLX) Chart for Wednesday, November, 22, 2017